Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 1,568 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Regimen Clear all

Conditions: Diabetes Mellitus
Interventions: Texting; Behavioral
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Articular Cartilage Disorder of Knee, Articular Cartilage; Degeneration
Interventions: Autologous peripheral blood stem cells and hyaluronic acid, Hyaluronic acid; Biological · Other
Lead sponsor: KLSMC Stem Cells, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Gulf Breeze, Florida

Conditions: Venous Leg Ulcer
Interventions: EpiFix, Compression Therapy; Other
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 5
States / cities: Boca Raton, Florida • Framingham, Massachusetts • Tulsa, Oklahoma + 2 more

Conditions: Urge Urinary Incontinence, Overactive Bladder
Interventions: Botulinum toxin A (Botox A®), Solifenacin 5mg, Solifenacin 10mg, Trospium chloride; Drug
Lead sponsor: NICHD Pelvic Floor Disorders Network; Network
Eligibility: 21 Years and older · Female only
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 11
States / cities: Birmingham, Alabama • La Jolla, California • San Diego, California + 8 more

Conditions: Treatment Resistant Depressive Disorder
Interventions: Esketamine 14 mg, Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 20 Years to 64 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 14
States / cities: Birmingham, Alabama • Garden Grove, California • Hartford, Connecticut + 11 more

Conditions: Hemophilia A
Interventions: rFVIIIFc; Biological
Lead sponsor: Bioverativ, a Sanofi company; Industry
Eligibility: Up to 5 Years · Male only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 20
States / cities: Little Rock, Arkansas • Duarte, California • Sacramento, California + 16 more

Conditions: Macular Degeneration, Choroidal Neovascularization
Interventions: Verteporfin photodynamic therapy, Pegaptanib, Triamcinolone acetonide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Virus Diseases, HIV
Interventions: Switch NRTIs as a Backbone to Raltegravir; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Type 1 Diabetes Mellitus
Interventions: Continuous Glucose Sensor, Standard Care, CGS + Behavior Therapy; Device · Other · Behavioral
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 11 Years to 16 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Amyotrophic Lateral Sclerosis
Interventions: CNM-Au8, Matching Placebo; Drug
Lead sponsor: Merit E. Cudkowicz, MD; Other
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pediatrics, Medically Complex, Children With Medical Complexity (CMC), Nursing
Interventions: CHAMP App; Device
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 0 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: HIV
Interventions: Atazanavir, Placebo; Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 45 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cystic Fibrosis-related Diabetes
Interventions: Bionic Pancreas, Usual Care; Device · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 10 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Graves' Ophthalmopathy (GO)
Interventions: RVT-1401 (Administered via subcutaneous injection), Placebo (Administered via subcutaneous injection); Drug · Other
Lead sponsor: Immunovant Sciences GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 12
States / cities: Beverly Hills, California • Pasadena, California • Miami, Florida + 9 more

Conditions: Down Syndrome, Intellectual Disability
Interventions: Memantine, Placebo; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 15 Years to 32 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hypoalbuminemia
Interventions: Specimen collection; Procedure
Lead sponsor: Akron Children's Hospital; Other
Eligibility: Not listed
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Mantua, Ohio

Conditions: Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: management of therapy complications; Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 65 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cervical Intraepithelial Neoplasia
Interventions: ADXS11-001 (Lm-LLO-E7), Placebo Control; Biological · Drug
Lead sponsor: Advaxis, Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 15
States / cities: Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 10 more

Conditions: Complications, Pregnancy
Interventions: Betamethasone; Drug
Lead sponsor: The George Washington University Biostatistics Center; Other
Eligibility: Female only
Enrollment: 486 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2007
U.S. locations: 19
States / cities: Birmingham, Alabama • Miami, Florida • Chicago, Illinois + 15 more

Conditions: Cytomegalovirus (CMV) Infections
Interventions: V160, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years to 35 Years · Female only
Enrollment: 2,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 54
States / cities: Birmingham, Alabama • Chandler, Arizona • Rialto, California + 41 more

Conditions: Arthritis, Gouty
Interventions: Indomethacin, Celecoxib; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 402 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 43
States / cities: Glendale, Arizona • Mesa, Arizona • Paradise Valley, Arizona + 37 more

Conditions: Eosinophilic Esophagitis
Interventions: EUR-1100, placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 12 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 7
States / cities: Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 4 more

Conditions: Radiation Dermatitis
Interventions: Chlorhexidine gluconate solution, Mupirocin Ointment; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: premeal insulin lispro mixtures, insulin glargine, metformin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Search by objective public record fields.

Texting for Diabetes

Efficacy and Safety Study of Intra-Articular Injections of Autologous Peripheral Blood Stem Cells Following Subchondral Drilling Surgery for the Treatment of Articular Cartilage Injury in the Knee

Human Amniotic Membrane Grafting and Standard of Care Versus Standard of Care Alone in the Treatment of Venous Leg Ulcers

Anticholinergic vs. Botox Comparison Study

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A

A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib

A Pilot,Raltegravir Versus NRTIs as a Backbone Switched From a Stable Boosted PI Regimen

Use of Continuous Glucose Sensors by Adolescents With Inadequate Diabetic Control

HEALEY ALS Platform Trial - Regimen C CNM-Au8

Parental Adherence of a Mobile Application

Atazanavir and Endothelial Function in Older HIV Patients

Feasibility of Outpatient Closed Loop Control With the iLet Bionic Pancreas in Cystic Fibrosis Related Diabetes

ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )

Down Syndrome Memantine Follow-up Study

Valproic Acid-associated Hypoalbuminemia in Medically Fragile Patients

Nerve Function in Older Diabetic Patients Who Are Undergoing Chemotherapy for Metastatic Solid Tumors

An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+

Repeat Antenatal Steroids Trial

V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002)

Celebrex In Acute Gouty Arthritis Study

Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis

Bacterial Decolonization to Prevent Radiation Dermatitis

Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes